DrugPatentWatch Database Preview
Details for Patent: 7,906,542
» See Plans and Pricing
Which drugs does patent 7,906,542 protect, and when does it expire?
Patent 7,906,542 protects XIFAXAN and is included in two NDAs.
This patent has ninety-four patent family members in thirty-seven countries.
Summary for Patent: 7,906,542
| Title: | Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin |
| Abstract: | Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin .alpha. and rifaximin .beta., and a poorly crystalline form referred to as rifaximin .gamma., useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention. |
| Inventor(s): | Viscomi; Giuseppe Claudio (Bologna, IT), Campana; Manuela (Bologna, IT), Braga; Dario (Bologna, IT), Confortini; Donatella (Bologna, IT), Cannata; Vincenzo (Bologna, IT), Righi; Paolo (Bologna, IT), Rosini; Goffredo (Bologna, IT) |
| Assignee: | Alfa Wassermann, S.p.A. (Bologna, IT) |
| Application Number: | 12/119,622 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,906,542 |
|
Patent Claim Types: see list of patent claims | Composition; Dosage form; Formulation; |
Drugs Protected by US Patent 7,906,542
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-001 | May 25, 2004 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 022554-001 | Mar 24, 2010 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,906,542
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 043547 | Start Trial | |||
| Argentina | 081991 | Start Trial | |||
| Argentina | 081992 | Start Trial | |||
| Austria | 361927 | Start Trial | |||
| Austria | 421965 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
